drugset / Trial / NCT06285201
Study of Felzartamab in Healthy Adult Subjects
RandomizedCrossoverQuadruple-blindHealth-services research
Summary
A Phase 1 Clinical Study to Evaluate the Pharmacokinetic Comparability, Safety, Tolerability, and Immunogenicity of Felzartamab for Injection Pre- and Post-changes of Process in Healthy Male Adult Subjects in China (Randomized, Double-blind, Single-dose, Two-formulation, Two-sequence, Two-period Crossover Design)
Timeline
- Start
- 2024-03-27
- Primary completion
- 2024-08-15
- Completion
- 2024-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Felzartamab | Monoclonal antibody | 8 mg/kg | Intravenous |
Indications
No indication recorded.